<code id='519AAF02C2'></code><style id='519AAF02C2'></style>
    • <acronym id='519AAF02C2'></acronym>
      <center id='519AAF02C2'><center id='519AAF02C2'><tfoot id='519AAF02C2'></tfoot></center><abbr id='519AAF02C2'><dir id='519AAF02C2'><tfoot id='519AAF02C2'></tfoot><noframes id='519AAF02C2'>

    • <optgroup id='519AAF02C2'><strike id='519AAF02C2'><sup id='519AAF02C2'></sup></strike><code id='519AAF02C2'></code></optgroup>
        1. <b id='519AAF02C2'><label id='519AAF02C2'><select id='519AAF02C2'><dt id='519AAF02C2'><span id='519AAF02C2'></span></dt></select></label></b><u id='519AAF02C2'></u>
          <i id='519AAF02C2'><strike id='519AAF02C2'><tt id='519AAF02C2'><pre id='519AAF02C2'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:68
          A sign of Lilly on the top of its biotechnology center — coverage from STAT
          Adobe

          Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

          In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

          advertisement

          In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Following judge's order, DOJ releases slightly less
          Following judge's order, DOJ releases slightly less

          3:32ApolicecarisseenoutsideformerUSPresidentDonaldTrump'sresidenceinMar-A-Lago,Fla.onAug.8,2022.Gior

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Search warrant issued in 1996 disappearance of Kristin Smart

          1:31AnundatedphotoreleasedbytheFBIshowsKristinSmart,theCaliforniaPolytechnicStateUniversity,SanLuisO